Aguirre Jarrad Mattieu sold $4K of LYEL
Aguirre Jarrad Mattieu (Chief Medical Officer) sold 422 shares of Lyell Immunopharma, Inc. (LYEL) at $8.63 on 2026-10-12.
How this was made
The 30-second read
Why it matters
A small discretionary sale by a senior executive typically has limited price impact but can be a minor bearish cue.
Market read
The filing provides a fresh, low‑impact data point for LYEL; unlikely to move the stock significantly.
What to watch
Potential upcoming clinical data releases that could offset the minor sell pressure.
Background
Form 4 filings disclose insider transactions; traders monitor them for signals of insider confidence.
Ticker impact
Chief Medical Officer sold 422 shares for $3,642 on 2026-10-12, reducing his stake to 19,857 shares.
likely modest downward pressure as the market prices the insider sale
The sale is small ($3.6k) and not part of a 10b5-1 plan, suggesting a discretionary sell rather than a routine diversification.
Market effects
None; the sale is company‑specific and does not affect the broader biotech sector.
None; limited to LYEL shareholders.
None
Counterpoint
The insider may be reallocating capital, not indicating lack of confidence; the sell could be neutral.
Key entities
- CompanyLyell Immunopharma, Inc.
Biotech firm developing immunotherapy treatments.
- PersonAguirre Jarrad Mattieu
Chief Medical Officer of Lyell Immunopharma.